Surge In Infectious Diseases Fueling The Growth Of The Market Due To Rising Disease Prevalence And Urgent Need For Effective Control Is Supporting Development Across The Preventive Vaccines Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Preventive Vaccines Market?

The market for preventive vaccines has seen robust expansion recently. This market is projected to expand from $83 billion in 2025 to reach $90.33 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.8%. Historically, this growth has been driven by factors such as the successful eradication and management of infectious diseases, various government-led vaccination campaigns, heightened public health consciousness, the establishment of worldwide immunization schemes, and increased financial contributions from international health bodies.

The preventive vaccines market size is projected to experience robust expansion over the next few years. It is expected to reach $131.27 billion in 2030, growing at a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period is attributable to several factors, including the evolution of next-generation vaccine platforms, an increasing global population and urbanization, heightened outbreak preparedness initiatives, the enlargement of adult immunization programs, and a rise in public-private partnerships focused on vaccine development. Prominent trends observed within this period encompass the extension of national immunization programs, a stronger emphasis on preventive healthcare and disease control, a growing need for pediatric and geriatric vaccinations, an increase in combination and multivalent vaccines, and the reinforcement of cold chain and vaccine storage infrastructure.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

What Important Drivers Are Powering The Preventive Vaccines Market Growth?

The future expansion of the preventive vaccines market is anticipated to be fueled by the rising occurrence of infectious diseases. These diseases are defined as ailments resulting from pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, capable of spreading among individuals or via environmental factors. Key contributors to this surge in infectious disease prevalence include heightened urbanization, extensive global travel, and growing antimicrobial resistance, all of which contribute to quicker dissemination and greater difficulty in managing infections. Preventive vaccines play a crucial role in managing infectious diseases by priming the immune system to identify and combat pathogens prior to the onset of infection, thus decreasing the occurrence and spread of illness. An illustrative example is the report from 2024 by the World Health Organization, a Switzerland-based intergovernmental body, which indicated that newly identified global cases of TB (tuberculosis) totaled 8.2 million in 2023, up from 7.5 million in 2022. Consequently, the escalating incidence of infectious diseases is a primary catalyst for the expansion of the preventive vaccines market.

What Are The Major Segment Categories Within The Preventive Vaccines Market?

The preventive vaccines market covered in this report is segmented –

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines

2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels

Subsegments:

1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine

2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine

3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine

4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine

5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine

6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines

7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

What Trends Are Influencing The Preventive Vaccines Market Outlook?

Leading companies in the preventive vaccines market are dedicating efforts to progress in vaccine technology, notably advanced mRNA technology platforms. This focus aims to boost vaccine effectiveness, refine safety profiles, enable quicker development and manufacturing processes, and deliver broader protection against novel variants of infectious diseases. Advanced mRNA technology platforms denote innovative methodologies that utilize messenger RNA to guide cells in producing specific proteins, thereby initiating a targeted immune response. For instance, in March 2025, Moderna Inc., a US-based biotechnology company, announced that mRNA-1283 (mNEXSPIKE), a new COVID-19 vaccine, received FDA approval. This vaccine is authorized for adults aged 65 and older and for individuals aged 12–64 who have one or more risk factors as defined by the CDC. The debut of mNEXSPIKE represents a considerable stride in next-generation mRNA vaccine technology, offering superior stability and easier storage conditions compared to earlier versions. This advancement is expected to improve vaccine accessibility and distribution, especially in remote and underserved regions.

Which Firms Are Competing In The Preventive Vaccines Market?

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Access The Complete Preventive Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Which Regional Market Leads The Preventive Vaccines Market?

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Preventive Vaccines Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24667&type=smp

Browse Through More Reports Similar to the Global Preventive Vaccines Market 2026, By The Business Research Company

Adult Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Travel Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795